{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T06:12:07Z","timestamp":1760076727090,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.gcb.2009.11.005","type":"journal-article","created":{"date-parts":[[2010,11,26]],"date-time":"2010-11-26T04:13:03Z","timestamp":1290744783000},"page":"125-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Are we turning to more than a first line treatment of metastatic colorectal cancer with high dose irinotecan ?: A monocentric institution safety analysis of 46 patients"],"prefix":"10.1016","volume":"35","author":[{"given":"L.","family":"Mineur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Sabatier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Kirscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Plat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Goubely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Molinari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gcb.2009.11.005_bib0005","doi-asserted-by":"crossref","unstructured":"Tournigand C, Andr\u00e9 T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J clin Oncol 2004;22(2):229\u201337.","DOI":"10.1200\/JCO.2004.05.113"},{"key":"10.1016\/j.gcb.2009.11.005_bib0010","doi-asserted-by":"crossref","unstructured":"Colucci G, Gebbia V, Paoletti G et al. Phase III randomised trial of FOLFIRI versus FOLFOX4 in treatment of Advanced Colorectal Cancer: A multicenter Study of the Gruppo Oncologico Dell\u2019Italia Meridionale. J clin Oncol 23:4866\u201375.","DOI":"10.1200\/JCO.2005.07.113"},{"key":"10.1016\/j.gcb.2009.11.005_bib0015","doi-asserted-by":"crossref","unstructured":"Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000.","DOI":"10.1016\/S0140-6736(00)02034-1"},{"issue":"23","key":"10.1016\/j.gcb.2009.11.005_bib0020","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gcb.2009.11.005_bib0025","doi-asserted-by":"crossref","unstructured":"E. Van Cutsem, M. Nowacki, I. Lang, S. Cascinu, I. Shchepotin, J. Maurel, P et al. Randomized phase III study of irinotecan and 5-FU\/FA with or without cetuximab in the firstline treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial Journal of Clinical Oncology, Annual Meeting Proceedings. Vol 25, No 18S (June 20 Supplement), 2007:4000.","DOI":"10.1200\/jco.2007.25.18_suppl.4000"},{"key":"10.1016\/j.gcb.2009.11.005_bib0030","doi-asserted-by":"crossref","unstructured":"Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: irinotecan Study Group. N Engl J Med 2000;343:905\u201314.","DOI":"10.1056\/NEJM200009283431302"},{"issue":"9","key":"10.1016\/j.gcb.2009.11.005_bib0035","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/00001813-200410000-00003","volume":"15","author":"Saigi","year":"2004","journal-title":"Anticancer Drugs"},{"issue":"3","key":"10.1016\/j.gcb.2009.11.005_bib0040","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00280-006-0372-9","article-title":"Multicenter phase II study sing increasing doses or irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer","volume":"60","author":"Duffour","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.gcb.2009.11.005_bib0045","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00280-002-0506-7","article-title":"High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer","volume":"50","author":"Ychou","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.gcb.2009.11.005_bib0050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000138352","article-title":"High dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases?","volume":"74","author":"Ducreux","year":"2008","journal-title":"Oncology"},{"key":"10.1016\/j.gcb.2009.11.005_bib0055","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(03)12461-0","article-title":"Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicenter randomised trial","volume":"361","author":"Maughan","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.gcb.2009.11.005_bib0060","doi-asserted-by":"crossref","unstructured":"F. Maindrault-Goebel, G. Lledo, B. Chibaudel, L. Mineur, T. Andre, M. Bennamoun, M et al. GERCOR OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study. J Clin Oncol 2006 ASCO Annual Meeting Proceedings, 2006:24, 3504, [18S].","DOI":"10.1200\/jco.2006.24.18_suppl.3504"},{"key":"10.1016\/j.gcb.2009.11.005_bib0065","doi-asserted-by":"crossref","unstructured":"Del Rio M, Molina F, Bascoul-Mollevi C Copois V, Bibeau F, Chalbos P et al. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol 2007;25:773\u201380.","DOI":"10.1200\/JCO.2006.07.4187"},{"key":"10.1016\/j.gcb.2009.11.005_bib0070","doi-asserted-by":"crossref","unstructured":"Maitland ML, DiRienzo A, Ratain MJ et al. Interpreting disparate responses to cancer therapy: the role of human population genetics. J Clin Oncol 2006;24:2151\u20137.","DOI":"10.1200\/JCO.2005.05.2282"},{"key":"10.1016\/j.gcb.2009.11.005_bib0075","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1158\/1078-0432.1226.11.3","article-title":"UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine\/irinotecan","volume":"11","author":"Carlini","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.gcb.2009.11.005_bib0080","unstructured":"Phelip JM. Cetuximab and combination chemotherapy as first-line therapy in treating patients with colorectal cancer that has spread to the liver and\/or Lung. http:\/\/clinicaltrials.gov."},{"key":"10.1016\/j.gcb.2009.11.005_bib0085","doi-asserted-by":"crossref","unstructured":"Rivoire M., Thezenas S., Rebischung C., Viret F., Guimbaud R., Francois E. et al. Preliminary results of a randomized phase II trial comparing standard bi-therapy versus three intensified chemotherapy regimens as treatment for patients with non resectable liver metastases from colorectal cancer (LMCRC). (METHEP) J Clin Oncol, 2008 ASCO Annual Meeting Proceedings. 26, No 15S (May 20 Supplement), 2008:4075.","DOI":"10.1200\/jco.2008.26.15_suppl.4075"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399832010000400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399832010000400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:36:07Z","timestamp":1760074567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399832010000400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S0399832010000400"],"URL":"https:\/\/doi.org\/10.1016\/j.gcb.2009.11.005","relation":{},"ISSN":["2210-7401"],"issn-type":[{"type":"print","value":"2210-7401"}],"subject":[],"published":{"date-parts":[[2011,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are we turning to more than a first line treatment of metastatic colorectal cancer with high dose irinotecan ?: A monocentric institution safety analysis of 46 patients","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gcb.2009.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}